

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	3	"7265123"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/11/27 09:49
L2	0	us2006216288	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/11/27 09:49
L3	2	"2006216288"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/11/27 09:50
L4	2	"20060216288"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/11/27 09:50
L6	8608	"Spector".in. or "Xia".in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/11/27 09:52
L7	2	l6 and (craf-1 or craf1)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/11/27 09:53
L8	0	(craf-1 or craf1) same combin?	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/11/27 09:53
L9	119	(craf-1 or craf1) same erbb2	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/11/27 09:53

EAST Search History

S1	16	"6268391"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/11/27 09:48
S2	3	"7084147"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 10:27
S3	5	"6719339"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 10:27
S4	3	"7109333"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 10:50
S5	9	"6727256"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 14:04
S6	2	"7189734"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/11/27 09:51
S7	2	"7141576"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 11:11
S8	12	"6713485"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 11:11

EAST Search History

S9	7	"bRaf inhibitor"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 14:38
S10	64	"Raf inhibitor"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 14:38
S11	55	"Raf inhibitor" and "cancer"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 14:40
S12	10	"b-Raf inhibitor" and "cancer"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 15:33
S13	0	514/264.110	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 15:34
S14	0	514/264.110.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 15:34
S15	0	514/264.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 15:34
S16	166	514/264.11.ccls.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 15:34

EAST Search History

S17	22	514/264.11.ccls. and ("erbb2" or "raf")	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2007/04/16 15:35
-----	----	---	--	----	-----	------------------

11/27/07

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/Capplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/Capplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 12	AUG 13	CA/Capplus enhanced with additional kind codes for granted patents
NEWS 13	AUG 20	CA/Capplus enhanced with CAS indexing in pre-1907 records
NEWS 14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 15	AUG 27	USPATOLD now available on STN
NEWS 16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 18	SEP 13	FORIS renamed to SOFIS
NEWS 19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 20	SEP 17	CA/Capplus enhanced with printed CA page images from 1967-1998
NEWS 21	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23	OCT 02	CA/Capplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 24	OCT 19	BEILSTEIN updated with new compounds
NEWS 25	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 26	NOV 19	WPIX enhanced with XML display format

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:44:02 ON 27 NOV 2007

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:44:14 ON 27 NOV 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 NOV 2007 HIGHEST RN 955995-34-3

DICTIONARY FILE UPDATES: 26 NOV 2007 HIGHEST RN 955995-34-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10510542_specie.str



chain nodes :

11 18 19 20 27 33 34 35 36 37 38

ring nodes :

1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 21 22 23 24 25 26 28
29 30 31 32

chain bonds :

3-28 7-11 11-12 15-19 16-18 19-20 20-21 25-27 30-33 33-34 34-35 35-36
36-37 37-38

ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
 15-16 16-17 21-22 21-26 22-23 23-24 24-25 25-26 28-29 28-32 29-30 30-31
 31-32
 exact/norm bonds :
 7-11 11-12 15-19 28-29 28-32 29-30 30-31 31-32
 exact bonds :
 3-28 16-18 19-20 20-21 25-27 30-33 33-34 34-35 35-36 36-37 37-38
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
 15-16 16-17 21-22 21-26 22-23 23-24 24-25 25-26

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
 20:CLASS 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:CLASS 28:Atom
 29:Atom 30:Atom 31:Atom 32:Atom 33:CLASS 34:CLASS 35:CLASS 36:CLASS
 37:CLASS 38:CLASS

L1 STRUCTURE UPLOADED

=> d l1
 L1 HAS NO ANSWERS
 L1 STR
 *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


Structure attributes must be viewed using STN Express query preparation.

=> s l1 exa full
 FULL SEARCH INITIATED 09:44:41 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 26 TO ITERATE
 100.0% PROCESSED 26 ITERATIONS 1 ANSWERS
 SEARCH TIME: 00.00.01

L2 1 SEA EXA FUL L1

=> d l2

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 231277-92-2 REGISTRY
 ED Entered STN: 07 Aug 1999
 CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-
 [[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)
 OTHER NAMES:
 CN 4-[[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[2-
 methanesulfonylethyl]amino]methyl]furan-2-yl]quinazoline
 CN GSK 572016
 CN GW 572016
 CN Lapatinib
 MF C29 H26 Cl F N4 O4 S
 CI COM
 SR CA
 LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, CA, CAPLUS, CASREACT, CBNB,
 CHEMCATS, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, PROUSDDR,
 RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

216 REFERENCES IN FILE CA (1907 TO DATE)
 4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 218 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file medline caplus wpids uspatfull
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
60.20	60.41

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 09:45:00 ON 27 NOV 2007

FILE 'CAPLUS' ENTERED AT 09:45:00 ON 27 NOV 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 09:45:00 ON 27 NOV 2007
 COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 09:45:00 ON 27 NOV 2007
 CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 12
 SAMPLE SEARCH INITIATED 09:45:04 FILE 'WPIDS'
 SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED	3 ITERATIONS	1 ANSWERS
SEARCH TIME: 00.00.01		

FULL FILE PROJECTIONS:	ONLINE	**COMPLETE**
	BATCH	**COMPLETE**
PROJECTED ITERATIONS:	3 TO	81
PROJECTED ANSWERS:	1 TO	40

L3 272 L2

=> s 13 and (craf-1 or craf1)
 L4 6 L3 AND (CRAF-1 OR CRAF1)

=> d 14 1-6 ibib, abs, hitstr

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:836903 CAPLUS

DOCUMENT NUMBER: 139:317433

TITLE: Cancer treatment method comprising administering an

erb-family inhibitor and a raf and/or ras inhibitor

INVENTOR(S): Spector, Neil Lee; Xia, Wenle

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 173 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003086467	A1	20031023	WO 2003-US10747	20030408
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003221684	A1	20031027	AU 2003-221684	20030408
EP 1492568	A1	20050105	EP 2003-718262	20030408
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005534623	T	20051117	JP 2003-583483	20030408
US 2005176740	A1	20050811	US 2004-510542	20041007
PRIORITY APPLN. INFO.:			US 2002-370807P	P 20020408
			WO 2003-US10747	W 20030408

OTHER SOURCE(S): MARPAT 139:317433

GI



AB The invention provides a method for treating cancer in a mammal, as well as pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and a Raf and/or ras inhibitor to a mammal suffering from a cancer. Preparation of compds., e.g. erbB-2/EGFR inhibitor I, is described.


IT 231277-92-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(erb-family inhibitor and raf and/or ras inhibitor combination for cancer treatment)

RN 231277-92-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2007:107539 USPATFULL

TITLE: HETEROCYCLIC COMPOUNDS

INVENTOR(S): COCKERILL, George Stuart, Maulden, UNITED KINGDOM
Lackey, Karen Elizabeth, Durham, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007093512	A1	20070426
	US 7265123	B2	20070904
APPLICATION INFO.:	US 2006-562047	A1	20061121 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2006-400284, filed on 7 Apr 2006, GRANTED, Pat. No. US 7189734 Division of Ser. No. US 2005-61578, filed on 18 Feb 2005, GRANTED, Pat. No. US 7084147 Division of Ser. No. US 2002-30527, filed on 9 Jan 2002, GRANTED, Pat. No. US 6933299		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-16213	19990709
	GB 1999-16218	19990709
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4376	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 231277-92-2

(preparation of anilinoquinazolines as protein tyrosine kinase inhibitors)

RN 231277-92-2 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-
[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)



L4 ANSWER 3 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2006:253838 USPATFULL

TITLE: Combinations for the treatment of cancer

INVENTOR(S): Chang, David, Calabasas, CA, UNITED STATES

PATENT ASSIGNEE(S): Amgen Inc, Thousand Oaks, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006216288	A1	20060928
APPLICATION INFO.:	US 2006-386271	A1	20060321 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-664381P	20050322 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AMGEN INC., MAIL STOP 28-2-C, ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320-1799, US	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	1584	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 231277-92-2

(combinations for the treatment of cancer)

RN 231277-92-2 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-
[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)



L4 ANSWER 4 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2006:222351 USPATFULL

TITLE: Anilinoquinazolines as protein tyrosine kinase inhibitors

INVENTOR(S): Cockerill, George Stuart, Maulden, UNITED KINGDOM
Lackey, Karen Elizabeth, Durham, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006189637	A1	20060824
	US 7189734	B2	20070313
APPLICATION INFO.:	US 2006-400284	A1	20060407 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2005-61578, filed on 18 Feb 2005, PENDING Division of Ser. No. US 2002-30527, filed on 9 Jan 2002, GRANTED, Pat. No. US 6933299		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-16213	19990709
	GB 1999-16218	19990709
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4471	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 231277-92-2

(preparation of anilinoquinazolines as protein tyrosine kinase inhibitors)

RN 231277-92-2 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-

[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)



L4 ANSWER 5 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2005:203315 USPATFULL

TITLE: Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor

INVENTOR(S): Spector, Neil Lee, Durham, NC, UNITED STATES
Xia, Wenle, Durham, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005176740	A1	20050811
APPLICATION INFO.:	US 2003-510542	A1	20030408 (10)
	WO 2003-US10747		20030408

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-370807P	20020408 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	

NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 3918

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and a Raf and/or ras inhibitor to a mammal suffering from a cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 231277-92-2P
(erb-family inhibitor and raf and/or ras inhibitor combination for cancer treatment)

RN 231277-92-2 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)



L4 ANSWER 6 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2005:165976 USPATFULL

TITLE: Anilinoquinazolines as protein tyrosine kinase inhibitors

INVENTOR(S): Cockerill, George Stuart, Maulden, UNITED KINGDOM
Lackey, Karen Elizabeth, Durham, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005143401	A1	20050630
	US 7084147	B2	20060801
APPLICATION INFO.:	US 2005-61578	A1	20050218 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-303527, filed on 25 Nov 2002, GRANTED, Pat. No. US 6719339		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-16213	19990709
	GB 1999-16218	19990709
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4418	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 231277-92-2

(preparation of anilinoquinazolines as protein tyrosine kinase inhibitors)

RN 231277-92-2 USPATFULL

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methanesulfonyl)ethyl]amino]methyl]-2-furanyl]- (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 09:44:02 ON 27 NOV 2007)

FILE 'REGISTRY' ENTERED AT 09:44:14 ON 27 NOV 2007

L1 STRUCTURE UPLOADED

L2 1 S L1 EXA FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 09:45:00 ON 27 NOV 2007

L3 272 S L2

L4 6 S L3 AND (CRAF-1 OR CRAF1)

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

47.63

108.04

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.78

-0.78

STN INTERNATIONAL LOGOFF AT 09:46:27 ON 27 NOV 2007